This company has been marked as potentially delisted and may not be actively trading.

UNITY Biotechnology (UBX) Competitors

UBX vs. AIMD, MBRX, HOOK, BFRI, and LIAN

Should you be buying UNITY Biotechnology stock or one of its competitors? The main competitors of UNITY Biotechnology include Ainos (AIMD), Moleculin Biotech (MBRX), HOOKIPA Pharma (HOOK), Biofrontera (BFRI), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry.

How does UNITY Biotechnology compare to Ainos?

UNITY Biotechnology (NASDAQ:UBX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

: Ainos has higher revenue and earnings than UNITY Biotechnology. Ainos is trading at a lower price-to-earnings ratio than UNITY Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UNITY Biotechnology N/A N/A -$25.99M -$1.62 N/A
Ainos $120K 103.66 -$14.77M -$3.53 N/A
: In the previous week, Ainos had 2 more articles in the media than UNITY Biotechnology. MarketBeat recorded 2 mentions for Ainos and 0 mentions for UNITY Biotechnology. Ainos' average media sentiment score of 1.00 beat UNITY Biotechnology's score of 0.00 indicating that Ainos is being referred to more favorably in the news media.
Company Overall Sentiment
UNITY Biotechnology Neutral
Ainos Positive
: UNITY Biotechnology has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500.
: UNITY Biotechnology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -140.10% beat UNITY Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
UNITY Biotechnology N/A -246.82% -58.81%
Ainos -11,912.10% -140.10% -62.97%
: 29.5% of UNITY Biotechnology shares are owned by institutional investors. 5.8% of UNITY Biotechnology shares are owned by insiders. Comparatively, 9.8% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: UNITY Biotechnology presently has a consensus price target of $1.50, suggesting a potential upside of 649.63%. Given UNITY Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe UNITY Biotechnology is more favorable than Ainos.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UNITY Biotechnology
0 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Ainos
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UNITY Biotechnology	N/A	N/A	-$25.99M	-$1.62	N/A
Ainos	$120K	103.66	-$14.77M	-$3.53	N/A

Company	Overall Sentiment
UNITY Biotechnology	Neutral
Ainos	Positive

Company	Net Margins	Return on Equity	Return on Assets
UNITY Biotechnology	N/A	-246.82%	-58.81%
Ainos	-11,912.10%	-140.10%	-62.97%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UNITY Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

UNITY Biotechnology and Ainos tied by winning 7 of the 14 factors compared between the two stocks.

How does UNITY Biotechnology compare to Moleculin Biotech?

UNITY Biotechnology (NASDAQ:UBX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

: UNITY Biotechnology is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UNITY Biotechnology N/A N/A -$25.99M -$1.62 N/A
Moleculin Biotech N/A N/A -$33.56M -$32.75 N/A
: In the previous week, Moleculin Biotech had 1 more articles in the media than UNITY Biotechnology. MarketBeat recorded 1 mentions for Moleculin Biotech and 0 mentions for UNITY Biotechnology. Moleculin Biotech's average media sentiment score of 0.84 beat UNITY Biotechnology's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Company Overall Sentiment
UNITY Biotechnology Neutral
Moleculin Biotech Positive
: UNITY Biotechnology has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
: Moleculin Biotech's return on equity of 0.00% beat UNITY Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
UNITY Biotechnology N/A -246.82% -58.81%
Moleculin Biotech N/A N/A -60.88%
: 29.5% of UNITY Biotechnology shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 5.8% of UNITY Biotechnology shares are held by insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: UNITY Biotechnology currently has a consensus price target of $1.50, suggesting a potential upside of 649.63%. Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 783.53%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than UNITY Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UNITY Biotechnology
0 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Moleculin Biotech
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UNITY Biotechnology	N/A	N/A	-$25.99M	-$1.62	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$32.75	N/A

Company	Overall Sentiment
UNITY Biotechnology	Neutral
Moleculin Biotech	Positive

Company	Net Margins	Return on Equity	Return on Assets
UNITY Biotechnology	N/A	-246.82%	-58.81%
Moleculin Biotech	N/A	N/A	-60.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UNITY Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Moleculin Biotech beats UNITY Biotechnology on 8 of the 13 factors compared between the two stocks.

How does UNITY Biotechnology compare to HOOKIPA Pharma?

UNITY Biotechnology (NASDAQ:UBX) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

: UNITY Biotechnology has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat UNITY Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
UNITY Biotechnology N/A -246.82% -58.81%
HOOKIPA Pharma -785.66% -120.09% -77.14%
: UNITY Biotechnology has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
: UNITY Biotechnology has higher earnings, but lower revenue than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than UNITY Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UNITY Biotechnology N/A N/A -$25.99M -$1.62 N/A
HOOKIPA Pharma $9.35M 1.56 -$43.50M -$3.54 N/A
: UNITY Biotechnology currently has a consensus price target of $1.50, suggesting a potential upside of 649.63%. Given UNITY Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe UNITY Biotechnology is more favorable than HOOKIPA Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UNITY Biotechnology
0 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
HOOKIPA Pharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 29.5% of UNITY Biotechnology shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 5.8% of UNITY Biotechnology shares are held by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, UNITY Biotechnology's average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score.
Company Overall Sentiment
UNITY Biotechnology Neutral
HOOKIPA Pharma Neutral

Company	Net Margins	Return on Equity	Return on Assets
UNITY Biotechnology	N/A	-246.82%	-58.81%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UNITY Biotechnology	N/A	N/A	-$25.99M	-$1.62	N/A
HOOKIPA Pharma	$9.35M	1.56	-$43.50M	-$3.54	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UNITY Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
UNITY Biotechnology	Neutral
HOOKIPA Pharma	Neutral

Summary

UNITY Biotechnology beats HOOKIPA Pharma on 9 of the 12 factors compared between the two stocks.

How does UNITY Biotechnology compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and UNITY Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

: In the previous week, Biofrontera had 1 more articles in the media than UNITY Biotechnology. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for UNITY Biotechnology. Biofrontera's average media sentiment score of 0.00 equaled UNITY Biotechnology'saverage media sentiment score.
Company Overall Sentiment
Biofrontera Neutral
UNITY Biotechnology Neutral
: 10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 29.5% of UNITY Biotechnology shares are owned by institutional investors. 4.8% of Biofrontera shares are owned by company insiders. Comparatively, 5.8% of UNITY Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: UNITY Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -25.26%. UNITY Biotechnology's return on equity of -246.82% beat Biofrontera's return on equity.
Company Net Margins Return on Equity Return on Assets
Biofrontera -25.26% -1,236.11% -56.67%
UNITY Biotechnology N/A -246.82% -58.81%
: Biofrontera has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, UNITY Biotechnology has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
: Biofrontera has higher revenue and earnings than UNITY Biotechnology. Biofrontera is trading at a lower price-to-earnings ratio than UNITY Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biofrontera $41.71M 0.33 -$10.54M -$1.03 N/A
UNITY Biotechnology N/A N/A -$25.99M -$1.62 N/A
: Biofrontera currently has a consensus price target of $2.75, suggesting a potential upside of 141.23%. UNITY Biotechnology has a consensus price target of $1.50, suggesting a potential upside of 649.63%. Given UNITY Biotechnology's higher possible upside, analysts clearly believe UNITY Biotechnology is more favorable than Biofrontera.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
UNITY Biotechnology
0 Sell rating(s)

2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Overall Sentiment
Biofrontera	Neutral
UNITY Biotechnology	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.26%	-1,236.11%	-56.67%
UNITY Biotechnology	N/A	-246.82%	-58.81%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.33	-$10.54M	-$1.03	N/A
UNITY Biotechnology	N/A	N/A	-$25.99M	-$1.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
UNITY Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

UNITY Biotechnology beats Biofrontera on 7 of the 13 factors compared between the two stocks.

How does UNITY Biotechnology compare to LianBio?

UNITY Biotechnology (NASDAQ:UBX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

: UNITY Biotechnology presently has a consensus target price of $1.50, suggesting a potential upside of 649.63%. Given UNITY Biotechnology's stronger consensus rating and higher possible upside, equities analysts clearly believe UNITY Biotechnology is more favorable than LianBio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UNITY Biotechnology
0 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
LianBio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: LianBio's return on equity of -33.17% beat UNITY Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
UNITY Biotechnology N/A -246.82% -58.81%
LianBio N/A -33.17% -30.19%
: LianBio is trading at a lower price-to-earnings ratio than UNITY Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
UNITY Biotechnology N/A N/A -$25.99M -$1.62 N/A
LianBio N/A N/A -$110.29M -$0.81 N/A
: UNITY Biotechnology has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
: 29.5% of UNITY Biotechnology shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 5.8% of UNITY Biotechnology shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: In the previous week, UNITY Biotechnology's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.
Company Overall Sentiment
UNITY Biotechnology Neutral
LianBio Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UNITY Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
UNITY Biotechnology	N/A	-246.82%	-58.81%
LianBio	N/A	-33.17%	-30.19%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UNITY Biotechnology	N/A	N/A	-$25.99M	-$1.62	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Company	Overall Sentiment
UNITY Biotechnology	Neutral
LianBio	Neutral

Summary

UNITY Biotechnology and LianBio tied by winning 5 of the 10 factors compared between the two stocks.

Get UNITY Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UBX vs. The Competition

Export

Metric	UNITY Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.44M	$3.38B	$6.22B	$12.11B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	-0.12	34.89	28.56	27.26
Price / Sales	N/A	303.59	535.48	83.62
Price / Cash	N/A	125.30	43.35	54.56
Price / Book	0.51	7.16	9.88	6.90
Net Income	-$25.99M	$23.57M	$3.54B	$333.00M

UNITY Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UBX UNITY Biotechnology	1.4858 of 5 stars	$0.20 flat	$1.50 +649.6%	N/A	$3.44M	N/A	N/A	60
AIMD Ainos	0.8049 of 5 stars	$1.84 -0.3%	N/A	-34.4%	$13.63M	$120K	N/A	40	Positive News Upcoming Earnings
MBRX Moleculin Biotech	2.95 of 5 stars	$2.55 +0.4%	$22.00 +762.7%	-90.3%	$13.62M	N/A	N/A	20	Upcoming Earnings
HOOK HOOKIPA Pharma	N/A	$1.10 flat	N/A	-20.3%	$13.41M	$9.35M	N/A	160
BFRI Biofrontera	1.9721 of 5 stars	$1.13 flat	$2.75 +143.4%	+63.3%	$13.31M	$41.71M	N/A	70	News Coverage Positive News Upcoming Earnings Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UBX) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UNITY Biotechnology (UBX) Competitors

UBX vs. AIMD, MBRX, HOOK, BFRI, and LIAN

How does UNITY Biotechnology compare to Ainos?

Summary

How does UNITY Biotechnology compare to Moleculin Biotech?

Summary

How does UNITY Biotechnology compare to HOOKIPA Pharma?

Summary

How does UNITY Biotechnology compare to Biofrontera?

Summary

How does UNITY Biotechnology compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX vs. The Competition

UNITY Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

UNITY Biotechnology (UBX) Competitors

UBX vs. AIMD, MBRX, HOOK, BFRI, and LIAN

How does UNITY Biotechnology compare to Ainos?

Summary

How does UNITY Biotechnology compare to Moleculin Biotech?

Summary

How does UNITY Biotechnology compare to HOOKIPA Pharma?

Summary

How does UNITY Biotechnology compare to Biofrontera?

Summary

How does UNITY Biotechnology compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX vs. The Competition

UNITY Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools